PureIMS

PureIMS is a biotechnology startup founded in 2014 and headquartered in The Netherlands. The company is dedicated to improving the health and lives of patients through its innovative inhaled drug delivery system, Cyclops®, which is at the core of its product development strategy. The company's leadership team, comprised of seasoned life sciences executives, brings extensive experience from leading roles in mid-size and top-5 global Pharma companies, as well as successful service providers.

PureIMS' flagship product, Levodopa Cyclops®, is in the final stages of development as a rescue therapy for OFF-episodes in Parkinson's disease. Additionally, Colistin Cyclops® is already being marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. The company is also actively exploring other clinical programs, including Epinephrine Cyclops® for (food) allergy and impending anaphylaxis.

Furthermore, PureIMS collaborates with pharma/biotech partners to apply the Cyclops®-based inhalation route for their drug of choice, highlighting its potential as a versatile platform technology. The company recently secured a Venture Round investment on 03 April 2023, with backing from notable investors including Boost-UP Foundation, Linesbridge Pharma Group, Interventional Medical Device Solutions, and Carduso Capital.

Overall, PureIMS stands out as a promising player in the biotechnology and life sciences industry, with a strong focus on addressing significant unmet medical needs through safe and effective inhaled therapies.